November 2015 (University of California) Norah Terrault, MD, Professor of Medicine and Surgery, Director, Viral Hepatitis Center, UCSF ...

September 2015 (Medical News Today) A team of scientists has created a computer simulation of an enzyme called NS3 that plays an important role in helping the hepatitis C virus replicate and spread in the body. The discovery should aid ...

February 2016 (Discovery Medicine) Systematic Review – Full Text Abstract: Fas ligand (FasL, CD95L) is a 40-kDa type II transmembrane protein that binds to Fas (CD95) receptors and promotes programmed cell death. Fas receptors are expressed at higher levels in ...

May 2015 (CDC – Viral Hepatitis – Hepatitis C Information) The primary goals of conducting surveillance for viral hepatitis are to direct prevention and control activities for these diseases and to evaluate the impact of these activities. In 2000, there ...

November 2015 (HealthDay News) Article Most common reason for denial was “insufficient information to assess medical need Nearly half of Medicaid patients with chronic hepatitis C have been denied newer direct-acting antiviral medications, due to tight controls that states have ...

April 2015 (Medical News Today) Researchers have long known that patients with hepatitis C are at increased risk of liver cancer. But a new study recently presented at the European Association for the Study of the Liver’s 50th International Liver ...

March 2016 (HealthDay News) In the next 35 years, 320,000 patients expected to die, 157,000 to develop hepatocellular carcinoma The burden of hepatitis C virus (HCV) and associated disease is projected to remain considerable even in the era of oral ...

May 19, 2016 (CDC – Viral Hepatitis) The month of May is designated as Hepatitis Awareness Month in the United States, and May 19th is Hepatitis Testing Day. During May, CDC and its public health partners work to shed light ...

April 2016 (Medical News Today) In the multi-center C-EDGE Head-to-Head study, investigators randomized 255 patients to 12 weeks of treatment with elbasvir (an NS5A inhibitor) plus grazoprevir (an NS3/4A protease inhibitor) or the NS5A inhibitor sofosbuvir plus peginterferon and ribavirin ...

Guidelines for laboratory testing and result reporting, viral hepatitis serolgy training, signal-to-cut-off ratiois for commercially available assays – – CDC has recommended that a person be considered to have serologic evidence of HCV infection only after an anti-HCV screening-test-positive result ...